CN Patent

CN102026999B — 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物

Assigned to Incyte Corp · Expires 2014-03-05 · 12y expired

What this patent protects

本发明涉及氮杂环丁烷和环丁烷衍生物以及它们的组合物及使用和制备方法，它们是可用于治疗包括例如炎性疾病和自身免疫疾病以及癌症的JAK相关性疾病的JAK抑制剂。

USPTO Abstract

本发明涉及氮杂环丁烷和环丁烷衍生物以及它们的组合物及使用和制备方法，它们是可用于治疗包括例如炎性疾病和自身免疫疾病以及癌症的JAK相关性疾病的JAK抑制剂。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN102026999B
Jurisdiction: CN
Classification: —
Expires: 2014-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.